Status:
RECRUITING
Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Lead Sponsor:
University of Ulm
Collaborating Sponsors:
Fresenius Medical Care Deutschland GmbH
Conditions:
Chronic Inflammatory Demyelinating Polyneuropathy
Eligibility:
All Genders
18+ years
Brief Summary
This study is designed as an explorative study aiming at exploring safety and efficacy of immunoadsorption (IA) in patients with Chronic Inflammatory Demyelinating Poly-neuropathy (CIDP) compared to i...
Detailed Description
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune-inflammatory disease which mainly affects the myelin sheaths of peripheral nerves, leading to paresis and sensory deficits...
Eligibility Criteria
Inclusion
- Diagnosis of CIDP based on the EAN/PNS Guidelines on Diagnosis and Treatment of CIDP13
- age ≥ 18 years
- Willing and capable of giving written informed consent
- Currently receiving IVIg or MP treatment OR starting IVIg or MP treatment at baseline
Exclusion
- none
Key Trial Info
Start Date :
August 27 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 27 2029
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT07154524
Start Date
August 27 2025
End Date
August 27 2029
Last Update
September 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ulm
Ulm, Baden-Wurttemberg, Germany, 89081